CIRM-funded ALS Trial Enrolls First Patients; Therapy Produced by Israeli Firm
An Israeli firm backed with $16 million from the California stem cell agency today announced that it has enrolled the first patients in its phase three trial for a treatment for ALS, sometimes known as Lou Gehrig's disease.
The trial, the final one before possible approval for widespread use of the therapy, is expected to include about 200 patients. The …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.